Peptides / Growth hormone axis

Synthetic analog · 6 amino acids · 1,047.2 Da

Pasireotide

ApprovedNot banned in sport

Pasireotide (Signifor) is a somatostatin analog approved in the US and EU for Cushing's disease and acromegaly when surgery is not an option or fails. Studies in people tested it on blood sugar, tumor growth and growth hormone, and tracked side effects. PepBank shows 418 results on pasireotide from 57 studies in people, and 99 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Signifor

6 amino acids, from first to lastXXWKYF

Evidence level: Large trials in people418 of 517 results come from studies in people, including randomized trials.

Results in people

418

81% of 517 results

Results in animals

4% of 517 results

Results in lab cells

15% of 517 results

From computer models

0% of 517 results

Overview

Pasireotide at a glance

What it is	Synthetic analog, 6 amino acids
Approval	Approved in the US and EU (Signifor)
In sport	Not listed as banned by WADA
Studies	76 studies with results. All of them gave pasireotide, with 517 results. 418 in people21 in animals78 in lab cells
Best study in people	Randomized controlled trial with 358 people (2014)
Clinical trials	76 registered: 4 active or planned, 38 with posted results
Community use	Initial US Signifor diaspartate solution treatment in adults with Cushing's disease when pituitary surgery is not an option or has not been curative

The science

What is pasireotide?

Pasireotide is a cyclic six-residue somatostatin analog.

Amino acids in one chain

The history of pasireotide

2005
The oldest paper on pasireotide in PepBank is from 2005.
2006December
A registered trial of pasireotide started (NCT00434148).

Pasireotide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 6 amino acidsFrom the first amino acid to the last

X1XW+KY5F

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Pasireotide is a synthetic analog of 6 amino acids, with a ring, 4 changed amino acids.

Formula

C₅₈H₆₆N₁₀O₉

Molecular weight

1,047.2 g/mol

CAS number

396091-73-9

Target

Somatostatin receptors: agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 9941444, ChEMBL CHEMBL3349607, UNII 98H1T17066, DrugBank DB06663

Full sequence, SMILES and InChIKey

Three-letter sequence
cyclo[(4R)-4-(2-aminoethylcarbamoyloxy)-L-Pro-L-Phg-D-Trp-L-Lys-O-benzyl-L-Tyr-L-Phe]

InChIKey
VMZMNAABQBOLAK-DBILLSOUSA-N

SMILES
C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN

See charge, composition and 3D structure on the Scientific page

The evidence

What pasireotide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people418 of 517 results come from studies in people, including randomized trials.

Blood sugar

56 results · 50 in people · 6 animal

In postoperative dumping syndrome, pasireotide increased the lowest glucose level compared with placebo. Neurogastroenterology and motility, 2014

Top results

In postoperative dumping syndrome, pasireotide increased the lowest glucose level compared with placebo. (Neurogastroenterology and motility, 2014)
In Cushing's disease, drug-related high blood glucose occurred in 38.9% receiving pasireotide through the 24-month cut-off. (Pituitary, 2015)
In healthy men, pasireotide 600 μg was linked to higher blood sugar before meals than placebo. (Endocrine, 2012)

Cancer

58 results · 43 in people · 2 animal · 13 lab

In advanced lung or thymic carcinoids, month 9 disease control was 39.0% with pasireotide versus 33.3% with everolimus. The Lancet. Oncology, 2017

Top results

In advanced lung or thymic carcinoids, month 9 disease control was 39.0% with pasireotide versus 33.3% with everolimus. (The Lancet. Oncology, 2017)
In Cushing's disease, tumor shrinkage at month 6 occurred more frequently with pasireotide 900 μg than 600 μg twice daily. (Pituitary, 2020)
In corticotropinoma cells, the response to pasireotide was limited. (The Journal of endocrinology, 2016)

Hormones

36 results · 34 in people · 2 lab

In Cushing's disease patients with elevated baseline saliva cortisol receiving pasireotide, 37.3% had normal saliva cortisol at month 6. Endocrine, 2016

Top results

In Cushing's disease patients with elevated baseline saliva cortisol receiving pasireotide, 37.3% had normal saliva cortisol at month 6. (Endocrine, 2016)
During pasireotide treatment, normal urinary cortisol occurred in 13/81 patients at month 36 versus 42/81 at extension baseline. (Clinical endocrinology, 2019)
In cells from human pancreatic tumors, pasireotide reduced chromogranin A secretion at least as efficiently as octreotide. (Endocrine-related cancer, 2014)

Growth hormone and growth

35 results · 29 in people · 6 lab

In acromegaly, pasireotide LAR achieved biochemical control more often than octreotide LAR. The Journal of clinical endocrinology and metabolism, 2014

Top results

In acromegaly, pasireotide LAR achieved biochemical control more often than octreotide LAR. (The Journal of clinical endocrinology and metabolism, 2014)
In uncontrolled acromegaly, 15% achieved biochemical control with pasireotide 40 mg versus none with continued octreotide or lanreotide. (The lancet. Diabetes & endocrinology, 2014)
In healthy volunteers, pasireotide CAM4071 doses >5 mg reduced IGF-1 rapidly compared with pasireotide LAR. (Endocrine, 2024)

Overall treatment results

17 results · 17 in people

In Cushing's disease, 17 pasireotide monotherapy patients achieved urinary cortisol control at week 35. Frontiers in endocrinology, 2023

Top results

In Cushing's disease, 17 pasireotide monotherapy patients achieved urinary cortisol control at week 35. (Frontiers in endocrinology, 2023)
In acromegaly, symptoms generally improved during pasireotide LAR treatment. (Journal of clinical pharmacology, 2014)
In Cushing's disease patients, clinical improvements persisted during pasireotide treatment. (Clinical endocrinology, 2019)

Daily life and fitness

15 results · 15 in people

In pancreatectomy patients, quality-of-life measures showed no major differences between pasireotide and placebo. Annals of surgical oncology, 2016

Top results

In pancreatectomy patients, quality-of-life measures showed no major differences between pasireotide and placebo. (Annals of surgical oncology, 2016)
In hepatic cyst patients, questionnaire scores improved in both groups, including placebo, and did not differ between pasireotide and placebo. (European radiology, 2018)
In Cushing's disease patients, psychosocial scores improved less than physical problem scores during pasireotide treatment. (Journal of endocrinological investigation, 2020)

Pasireotide has 484 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 76 pasireotide studies by area Open the Scientific page

Key pasireotide studies

Studies in people come first, then studies in animals and in the lab.

People
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study
Colao et al. 2014 · The Journal of clinical endocrinology and metabolism · 358 people · cited by 294
5 results
People
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Gadelha et al. 2014 · The lancet. Diabetes & endocrinology · 133 people · cited by 278
10 results
People
Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula: A Randomized Clinical Trial
Tarvainen et al. 2020 · JAMA surgery · 126 people · cited by 49
5 results
People
Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study
Chéreau et al. 2016 · PloS one · 90 people · cited by 6
3 results
People
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
Wolin et al. 2015 · Drug design, development and therapy · 88 people · cited by 143
6 results

All 76 Pasireotide studies

Pasireotide clinical trials

ClinicalTrials.gov lists 76 trials of pasireotide. 4 are active or planned, and 38 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Phase 3completed439 people

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Phase 3completed358 people

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4completed337 people

All 45 Pasireotide trials

Status and safety

Is pasireotide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Signifor). The FDA label for Signifor says: “Adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Pasireotide side effects and safety

PepBank has 154 safety results from studies of pasireotide. 154 of them come from studies in people.

Safety results from studies (154)

After partial pancreatectomy, one pasireotide patient and 2 hydrocortisone patients died within 30 days. (JAMA surgery, 2020)
In mastectomy and axillary dissection patients, overall safety was comparable between pasireotide and placebo. (PloS one, 2016)
In these patients, high blood sugar occurred more often with pasireotide than placebo. (Clinical journal of the American Society of Nephrology, 2020)
In acromegaly, high-blood-sugar events occurred more often with pasireotide LAR than octreotide LAR. (The Journal of clinical endocrinology and metabolism, 2014)
In uncontrolled acromegaly, high blood sugar occurred in 33% with pasireotide 40 mg versus 14% with continued octreotide or lanreotide. (The lancet. Diabetes & endocrinology, 2014)
In refractory carcinoid tumors, drug-related high blood glucose was more frequent with pasireotide than octreotide. (Drug design, development and therapy, 2015)
In healthy volunteers, pasireotide 600 µg bid prolonged corrected QT by 13.2 milliseconds relative to placebo. (Journal of clinical pharmacology, 2014)
In healthy men, pasireotide 600 μg was linked to higher blood sugar before meals than placebo. (Endocrine, 2012)
In healthy volunteers, pasireotide CAM4071 injections ≤40 mg had tolerability comparable with currently available pasireotide formulations. (Endocrine, 2024)
After allogeneic HCT, severe gastrointestinal toxicity was numerically higher with pasireotide than matched controls, without a significant difference. (PloS one, 2021)
In patients with metastatic NETs, 79% had high blood sugar during pasireotide LAR treatment. (Endocrine-related cancer, 2015)
In advanced liver cancer patients, high blood sugar was the main toxicity during pasireotide treatment. (Journal of hepatocellular carcinoma, 2018)
In medullary thyroid cancer patients receiving pasireotide, diarrhoea was common and grade 3 diarrhoea occurred in 5.3%. (Endocrine, 2018)
In patients with acromegaly, thirteen (4%) stopped pasireotide because of adverse events related to high blood sugar. (Endocrine connections, 2020)
During pasireotide treatment, 88 of 190 participants with acromegaly did not need medication for high blood sugar. (Frontiers in endocrinology, 2024)
In patients with acromegaly, 23/173 stopped pasireotide because of adverse events. (European journal of endocrinology, 2020)
In Cushing's disease, drug-related diarrhea occurred in 55.6% receiving pasireotide through the 24-month cut-off. (Pituitary, 2015)
In the pasireotide extension, 39.5% of patients experienced adverse events related to high blood sugar. (Clinical endocrinology, 2019)
Healthy men receiving pasireotide had no unexpected side effects. (The Journal of clinical endocrinology and metabolism, 2013)
In patients with advanced NET receiving pasireotide, drug-related nausea occurred in 27%. (Endocrine-related cancer, 2012)
In Chinese healthy men receiving pasireotide formulations, 2 stopped the study because of adverse events. (Clinical therapeutics, 2014)
In dumping syndrome patients receiving pasireotide, 34.9% experienced headache. (Alimentary pharmacology & therapeutics, 2018)
In patients with advanced GEP NET, 81 % reported side effects during pasireotide LAR treatment. (Cancer chemotherapy and pharmacology, 2013)
In advanced lung or thymic carcinoids, 37% receiving pasireotide alone experienced suspected treatment-related grade 1-2 diarrhoea. (The Lancet. Oncology, 2017)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
40 mg/28 days, with optional titration to 60 mg at months 3 and 7	Human	human	Not reported	12 months	Randomized trial in people · n = 358	Colao 2014
40 mg every 28 days	Human	human	Not reported	24 weeks	Randomized trial in people · n = 133	Gadelha 2014
60 mg every 28 days	Human	human	Not reported	24 weeks	Randomized trial in people · n = 133	Gadelha 2014
900 μg twice a day	Human	human	subcutaneous	7 days	Randomized trial in people · n = 126	Tarvainen 2020
60 mg, one injection	Human	human	intramuscular	single injection 7 to 10 days before surgery	Randomized trial in people · n = 90	Chéreau 2016
60 mg every 28 days	Human	human	Not reported	Not reported	Randomized trial in people · n = 88	Wolin 2015
60 mg every 28 days	Human	human	intramuscular	Not reported	Randomized trial in people · n = 83	Ferolla 2017
60 mg long-acting release, two injections	Human	human	intramuscular	Injections 2 weeks before and 2 weeks after aspiration sclerotherapy	Randomized trial in people · n = 34	Wijnands 2018
900 μg twice daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 53	Lacroix 2020
60 mg every 28 days	Human	human	Not reported	6 months	Randomized trial in people · n = 22	Benamouzig 2018
600, 900, or 1200 μg twice a day across study arms	Human	human	subcutaneous	7 days	Randomized trial in people	Henry 2013
300 μg t.i.d.	Human	human	subcutaneous	2 weeks	Randomized trial in people	Deloose 2014
600 µg bid	Human	human	subcutaneous	Not reported	Randomized trial in people	Breitschaft 2014
1,950 µg bid	Human	human	subcutaneous	Not reported	Randomized trial in people	Breitschaft 2014
600 μg once daily	Human	human	subcutaneous	14 days	Randomized trial in people	Beglinger 2012
5, 10, 20, 40 or 80 mg	Human	human	subcutaneous	single dose	Randomized trial in people	Johnsson 2024
>5 mg	Human	human	subcutaneous	single dose	Randomized trial in people	Johnsson 2024
80 mg	Human	human	subcutaneous	single dose	Randomized trial in people	Johnsson 2024
≤40 mg	Human	human	subcutaneous	single dose	Randomized trial in people	Johnsson 2024
40 mg/28 days, adjustable to 10-60 mg/28 days	Human	human	Not reported	36 weeks	Trial in people without random groups · n = 123	Gadelha 2019
40 mg/28 days, with optional escalation to 60 mg/28 days	Human	human	Not reported	12 months	Trial in people without random groups · n = 81	Bronstein 2016
0.9mg every 12 hours	Human	human	Not reported	day prior to conditioning through day +4 after HCT, maximum 14 days	Trial in people without random groups · n = 78	Ramalingam 2021
20 mg, 40 mg, or 60 mg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 33	Tahara 2017
600 microg twice daily	Human	human	subcutaneous	15 days	Trial in people without random groups · n = 29	Boscaro 2009
60 mg every 4 weeks	Human	human	Not reported	Not reported	Trial in people without random groups · n = 29	Cives 2015
60 mg/m	Human	human	Not reported	at least 6 months	Trial in people without random groups · n = 19	Faggiano 2018
600, 900, or 1200 μg twice a day	Human	human	subcutaneous	7 days	Trial in people without random groups	Henry 2013
60 mg every 28 days	Human	human	intramuscular	Not reported	Trial in people without random groups · n = 20	Feun 2018
600 or 900 μg twice daily	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 67	Findling 2016
600 μg twice daily	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 19	Findling 2016
900 μg twice daily	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 14	Findling 2016
40 or 60 mg	Human	human	Not reported	24 weeks	Trial in people without random groups	Schmid 2016
40 mg/28 days	Human	human	intramuscular	up to 16 weeks (pre-randomization)	Trial in people without random groups · n = 190	Feldt-Rasmussen 2024
40 or 60 mg	Human	human	Not reported	Up to 304 weeks	Trial in people without random groups · n = 173	Colao 2020
600 μg twice daily	Human	human	subcutaneous	up to 16 weeks (pre-randomization)	Trial in people without random groups · n = 59	Feldt-Rasmussen 2024
300-1,200 μg bid	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 58	Schopohl 2015
600 or 900 μg twice daily	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 53	Lacroix 2020
150 μg twice daily, escalated to a maximum of 1200 μg twice daily	Human	human	subcutaneous	Not reported	Trial in people without random groups · n = 45	Kvols 2012
Initially 10 or 30 mg every 28 days, adjusted within 5-40 mg	Human	human	Not reported	12 months	Trial in people without random groups · n = 45	Lacroix 2020
single SC dose of 300, 600, or 900 μg on day 1, then the same dose BID; single IM dose of 20, 40, or 60 mg pasireotide LAR on day 33	Human	human	subcutaneous and intramuscular	Not reported	Trial in people without random groups · n = 45	Chen 2014

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label reports prescription use. The regimen below is label information.

Reported routines and cautions

What people use it for

Initial US Signifor diaspartate solution treatment in adults with Cushing's disease when pituitary surgery is not an option or has not been curativeS1

Reported regimens

Regimens that community sources report for Pasireotide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Initial US Signifor diaspartate solution treatment in adults with Cushing's disease when pituitary surgery is not an option or has not been curativeOfficial label dosing of an approved product	subcutaneous injection	0.6 to 0.9 mg per dose	twice daily	Not stated	Single official US label source.	S1

Cautions

The label warns about hyperglycemia, hypocortisolism, bradycardia, QT prolongation, liver test elevations, gallstones, pituitary hormone deficiency, and fat malabsorption.S1

Status notes

EMA authorises Signifor for adults with Cushing's disease when surgery is unsuitable or unsuccessful. Acromegaly also requires inadequate control with another somatostatin analog.S2

Community sources

S1Signifor US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This record covers one selected US label regimen. It does not establish a separate non-vendor community regimen. Duration is not a fixed course. The full label includes further monitoring, adverse-reaction management, patient groups, and administration instructions.

Questions and more

Ask a question about pasireotide

The answer links to every study it uses.

What does the evidence say about pasireotide?Is pasireotide tested in people?Compare with Lanreotide Compare with Octreotide

Sources

Database: PepBank data for pasireotide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about pasireotide

Pasireotide

ApprovedNot banned in sport

Also known as Signifor

What it is

Synthetic analog, 6 amino acids

Approval

Approved in the US and EU (Signifor)

In sport

Not listed as banned by WADA

Studies

76 studies with results. All of them gave pasireotide, with 517 results.
418 in people21 in animals78 in lab cells

Best study in people

Randomized controlled trial with 358 people (2014)

Clinical trials

76 registered: 4 active or planned, 38 with posted results

Community use

Initial US Signifor diaspartate solution treatment in adults with Cushing's disease when pituitary surgery is not an option or has not been curative

Dose as reported

Class

Species

Route

Duration

Design

Source

40 mg/28 days, with optional titration to 60 mg at months 3 and 7

Human

human

Not reported

12 months

Randomized trial in people · n = 358

Colao 2014

40 mg every 28 days

Human

human

Not reported

24 weeks

Randomized trial in people · n = 133

Gadelha 2014

60 mg every 28 days

Human

human

Not reported

24 weeks

Randomized trial in people · n = 133

Gadelha 2014

900 μg twice a day

Human

human

subcutaneous

7 days

Randomized trial in people · n = 126

Tarvainen 2020

60 mg, one injection

Human

human

intramuscular

single injection 7 to 10 days before surgery

Randomized trial in people · n = 90

Chéreau 2016

60 mg every 28 days

Human

human

Not reported

Randomized trial in people · n = 88

Wolin 2015

60 mg every 28 days

Human

human

intramuscular

Not reported

Randomized trial in people · n = 83

Ferolla 2017

60 mg long-acting release, two injections

Human

human

intramuscular

Injections 2 weeks before and 2 weeks after aspiration sclerotherapy

Randomized trial in people · n = 34

Wijnands 2018

900 μg twice daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 53

Lacroix 2020

60 mg every 28 days

Human

human

Not reported

6 months

Randomized trial in people · n = 22

Benamouzig 2018

600, 900, or 1200 μg twice a day across study arms

Human

human

subcutaneous

7 days

Randomized trial in people

Henry 2013

300 μg t.i.d.

Human

human

subcutaneous

2 weeks

Randomized trial in people

Deloose 2014

600 µg bid

Human

human

subcutaneous

Not reported

Randomized trial in people

Breitschaft 2014

1,950 µg bid

Human

human

subcutaneous

Not reported

Randomized trial in people

Breitschaft 2014

600 μg once daily

Human

human

subcutaneous

14 days

Randomized trial in people

Beglinger 2012

5, 10, 20, 40 or 80 mg

Human

human

subcutaneous

single dose

Randomized trial in people

Johnsson 2024

>5 mg

Human

human

subcutaneous

single dose

Randomized trial in people

Johnsson 2024

80 mg

Human

human

subcutaneous

single dose

Randomized trial in people

Johnsson 2024

≤40 mg

Human

human

subcutaneous

single dose

Randomized trial in people

Johnsson 2024

40 mg/28 days, adjustable to 10-60 mg/28 days

Human

human

Not reported

36 weeks

Trial in people without random groups · n = 123

Gadelha 2019

40 mg/28 days, with optional escalation to 60 mg/28 days

Human

human

Not reported

12 months

Trial in people without random groups · n = 81

Bronstein 2016

0.9mg every 12 hours

Human

human

Not reported

day prior to conditioning through day +4 after HCT, maximum 14 days

Trial in people without random groups · n = 78

Ramalingam 2021

20 mg, 40 mg, or 60 mg

Human

human

Not reported

Trial in people without random groups · n = 33

Tahara 2017

600 microg twice daily

Human

human

subcutaneous

15 days

Trial in people without random groups · n = 29

Boscaro 2009

60 mg every 4 weeks

Human

human

Not reported

Trial in people without random groups · n = 29

Cives 2015

60 mg/m

Human

human

Not reported

at least 6 months

Trial in people without random groups · n = 19

Faggiano 2018

600, 900, or 1200 μg twice a day

Human

human

subcutaneous

7 days

Trial in people without random groups

Henry 2013

60 mg every 28 days

Human

human

intramuscular

Not reported

Trial in people without random groups · n = 20

Feun 2018

600 or 900 μg twice daily

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 67

Findling 2016

600 μg twice daily

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 19

Findling 2016

900 μg twice daily

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 14

Findling 2016

40 or 60 mg

Human

human

Not reported

24 weeks

Trial in people without random groups

Schmid 2016

40 mg/28 days

Human

human

intramuscular

up to 16 weeks (pre-randomization)

Trial in people without random groups · n = 190

Feldt-Rasmussen 2024

40 or 60 mg

Human

human

Not reported

Up to 304 weeks

Trial in people without random groups · n = 173

Colao 2020

600 μg twice daily

Human

human

subcutaneous

up to 16 weeks (pre-randomization)

Trial in people without random groups · n = 59

Feldt-Rasmussen 2024

300-1,200 μg bid

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 58

Schopohl 2015

600 or 900 μg twice daily

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 53

Lacroix 2020

150 μg twice daily, escalated to a maximum of 1200 μg twice daily

Human

human

subcutaneous

Not reported

Trial in people without random groups · n = 45

Kvols 2012

Initially 10 or 30 mg every 28 days, adjusted within 5-40 mg

Human

human

Not reported

12 months

Trial in people without random groups · n = 45

Lacroix 2020

single SC dose of 300, 600, or 900 μg on day 1, then the same dose BID; single IM dose of 20, 40, or 60 mg pasireotide LAR on day 33

Human

human

subcutaneous and intramuscular

Not reported

Trial in people without random groups · n = 45

Chen 2014

Context

Route

Amount

How often

How long

Agreement

Sources

Initial US Signifor diaspartate solution treatment in adults with Cushing's disease when pituitary surgery is not an option or has not been curativeOfficial label dosing of an approved product

subcutaneous injection

0.6 to 0.9 mg per dose

twice daily

Not stated

Single official US label source.

Pasireotide

Pasireotide at a glance

What is pasireotide?

The history of pasireotide

Pasireotide structure and chemistry

What pasireotide studies show

Blood sugar

Cancer

Hormones

Growth hormone and growth

Overall treatment results

Daily life and fitness

Key pasireotide studies

Pasireotide clinical trials

Is pasireotide approved?

Pasireotide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about pasireotide

Related peptides

Sources

Pasireotide

Pasireotide at a glance

What is pasireotide?

The history of pasireotide

Pasireotide structure and chemistry

What pasireotide studies show

Blood sugar

Cancer

Hormones

Growth hormone and growth

Overall treatment results

Daily life and fitness

Key pasireotide studies

Pasireotide clinical trials

Is pasireotide approved?

Pasireotide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about pasireotide

Related peptides

Sources